92% of evaluable patients at interim analysis treated with RAD 101 achieved concordance¹ with MRI imaging (the primary endpoint) with significant and selective tumor uptake in suspected or recurrent ...
Quipt shareholders to receive US$3.65 per share in cash; Transaction provides immediate liquidity and certainty of value to shareholders; The per share purchase price represents a ...
Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, today announced new Direct Store Delivery (DSD) partnerships with Pine State Beverage, ...
"The success of BAM-1 Alpha is reshaping our production capabilities," said Kim Thompson, Founder and CEO of Kraig Labs. "These results reaffirm the power of this hybrid line, and to surpass the ...
Data from FDA-advised study demonstrates Lumee™ Oxygen tissue monitoring is a safe and effective long-term method in PAD patients and will support potential FDA submission; strongly correlates with ...
Under the agreement, Opes will leverage its existing commercial relationships and market experience to identify and engage potential customers primarily in Europe, Israel, and Asia to accelerate ...
About Roxadustat Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased ...
- Zenas acquired the exclusive right to develop, manufacture and commercialize orelabrutinib in the field of Multiple Sclerosis globally, and non-oncology fields in all territories outside Greater ...
Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients ...
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...
The CUTX-101 NDA was initially granted Priority Review by the FDA and is supported by positive topline clinical efficacy results for CUTX-101, demonstrating significant improvement in overall survival ...
The Company's audited financial statements, and related management’s discussion and analysis, in the form of an Annual Report on Form 10-K, for the three months and year ended September 30, 2025, are ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback